These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

865 related items for PubMed ID: 21745460

  • 1. Pharmacological profile of FK881(ASP6537), a novel potent and selective cyclooxygenase-1 inhibitor.
    Imanishi J, Morita Y, Yoshimi E, Kuroda K, Masunaga T, Yamagami K, Kuno M, Hamachi E, Aoki S, Takahashi F, Nakamura K, Miyata S, Ohkubo Y, Mutoh S.
    Biochem Pharmacol; 2011 Oct 01; 82(7):746-54. PubMed ID: 21745460
    [Abstract] [Full Text] [Related]

  • 2. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I.
    J Pharmacol Exp Ther; 1999 Aug 01; 290(2):551-60. PubMed ID: 10411562
    [Abstract] [Full Text] [Related]

  • 3. ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor.
    Harris RR, Black L, Surapaneni S, Kolasa T, Majest S, Namovic MT, Grayson G, Komater V, Wilcox D, King L, Marsh K, Jarvis MF, Nuss M, Nellans H, Pruesser L, Reinhart GA, Cox B, Jacobson P, Stewart A, Coghlan M, Carter G, Bell RL.
    J Pharmacol Exp Ther; 2004 Dec 01; 311(3):904-12. PubMed ID: 15277581
    [Abstract] [Full Text] [Related]

  • 4. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Léger S, Mancini JA, O'Neill G, Ouellet M, Rodger IW, Thérien M, Wang Z, Webb JK, Wong E, Chan CC.
    Br J Pharmacol; 1997 May 01; 121(1):105-17. PubMed ID: 9146894
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors.
    Gierse J, Nickols M, Leahy K, Warner J, Zhang Y, Cortes-Burgos L, Carter J, Seibert K, Masferrer J.
    Eur J Pharmacol; 2008 Jun 24; 588(1):93-8. PubMed ID: 18457826
    [Abstract] [Full Text] [Related]

  • 6. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
    Song Y, Connor DT, Sercel AD, Sorenson RJ, Doubleday R, Unangst PC, Roth BD, Beylin VG, Gilbertsen RB, Chan K, Schrier DJ, Guglietta A, Bornemeier DA, Dyer RD.
    J Med Chem; 1999 Apr 08; 42(7):1161-9. PubMed ID: 10197960
    [Abstract] [Full Text] [Related]

  • 7. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
    Song Y, Connor DT, Doubleday R, Sorenson RJ, Sercel AD, Unangst PC, Roth BD, Gilbertsen RB, Chan K, Schrier DJ, Guglietta A, Bornemeier DA, Dyer RD.
    J Med Chem; 1999 Apr 08; 42(7):1151-60. PubMed ID: 10197959
    [Abstract] [Full Text] [Related]

  • 8. Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
    King JN, Dawson J, Esser RE, Fujimoto R, Kimble EF, Maniara W, Marshall PJ, O'Byrne L, Quadros E, Toutain PL, Lees P.
    J Vet Pharmacol Ther; 2009 Feb 08; 32(1):1-17. PubMed ID: 19161451
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
    Rao PN, Chen QH, Knaus EE.
    J Med Chem; 2006 Mar 09; 49(5):1668-83. PubMed ID: 16509583
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor.
    Yoshino T, Kimoto A, Kobayashi S, Noguchi M, Fukunaga M, Hayashi A, Miyata K, Sasamata M.
    Arzneimittelforschung; 2005 Mar 09; 55(7):394-402. PubMed ID: 16080279
    [Abstract] [Full Text] [Related]

  • 11. Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
    Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, Koboldt CM, Muhammad JL, Zweifel BS, Masferrer JL, Isakson PC, Seibert K.
    J Pharmacol Exp Ther; 2005 Mar 09; 312(3):1206-12. PubMed ID: 15494548
    [Abstract] [Full Text] [Related]

  • 12. In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.
    Shin SS, Byun Y, Lim KM, Choi JK, Lee KW, Moh JH, Kim JK, Jeong YS, Kim JY, Choi YH, Koh HJ, Park YH, Oh YI, Noh MS, Chung S.
    J Med Chem; 2004 Feb 12; 47(4):792-804. PubMed ID: 14761182
    [Abstract] [Full Text] [Related]

  • 13. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach.
    Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, Hill RG, Li CS, Mancini J, Penneton M.
    J Pharmacol Exp Ther; 1995 Sep 12; 274(3):1531-7. PubMed ID: 7562530
    [Abstract] [Full Text] [Related]

  • 14. Discovery of a novel COX-2 inhibitor as an orally potent anti-pyretic and anti-inflammatory drug: design, synthesis, and structure-activity relationship.
    Hayashi S, Sumi Y, Ueno N, Murase A, Takada J.
    Biochem Pharmacol; 2011 Oct 01; 82(7):755-68. PubMed ID: 21741371
    [Abstract] [Full Text] [Related]

  • 15. Pharmacological profile of JTE-522, a novel prostaglandin H synthase-2 inhibitor, in rats.
    Matsushita M, Masaki M, Yagi Y, Tanaka T, Wakitani K.
    Inflamm Res; 1997 Nov 01; 46(11):461-6. PubMed ID: 9427067
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. New celecoxib derivatives as anti-inflammatory agents.
    Szabó G, Fischer J, Kis-Varga A, Gyires K.
    J Med Chem; 2008 Jan 10; 51(1):142-7. PubMed ID: 18072726
    [Abstract] [Full Text] [Related]

  • 18. Synthesis, anti-inflammatory activity and COX-1/COX-2 inhibition of novel substituted cyclic imides. Part 1: Molecular docking study.
    Abdel-Aziz AA, ElTahir KE, Asiri YA.
    Eur J Med Chem; 2011 May 10; 46(5):1648-55. PubMed ID: 21388719
    [Abstract] [Full Text] [Related]

  • 19. Cyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity.
    Ndengele MM, Cuzzocrea S, Esposito E, Mazzon E, Di Paola R, Matuschak GM, Salvemini D.
    FASEB J; 2008 Sep 10; 22(9):3154-64. PubMed ID: 18497304
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological separation between peripheral and central functions of cyclooxygenase-2 with CIAA, a novel cyclooxygenase-2 inhibitor.
    Okumura T, Murata Y, Hizue M, Matsuura T, Naganeo R, Kanai Y, Murase A, Sakakibara A, Fujita I, Nakao K.
    Eur J Pharmacol; 2006 Jun 06; 539(1-2):125-30. PubMed ID: 16690052
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.